|
1ZDT
The Crystal Structure of Human Steroidogenic Factor-1
Deposited 2005-04-14
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
221–461(241 aa)
|
Mutation:C247S, C412S
|
PEF DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;PEG3350, ammonium sulfate, sucrose, pH 5.5, temperature 277K, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.10 Å
R-free 0.265
|
|
1ZDT
The Crystal Structure of Human Steroidogenic Factor-1
Deposited 2005-04-14
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
221–461(241 aa)
|
Mutation:C247S, C412S
|
PEF DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;PEG3350, ammonium sulfate, sucrose, pH 5.5, temperature 277K, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.10 Å
R-free 0.265
|
|
1ZDT
The Crystal Structure of Human Steroidogenic Factor-1
Deposited 2005-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
221–461(241 aa)
Chain B
221–461(241 aa)
|
Mutation:C247S, C412S
Mutation:C247S, C412S
|
PEF DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;PEG3350, ammonium sulfate, sucrose, pH 5.5, temperature 277K, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.10 Å
R-free 0.265
|
|
4QJR
Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to its hormone pip3 at 2.4 a resolution
Deposited 2014-06-04
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
218–461(244 aa)
Fragment:UNP residues 218-461
|
Mutation:C247S, C412S
|
PIZ (2S)-3-{[(R)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane -1,2-diyl dihexadecanoate × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;10% PEG 8K, 0.025M MGOAC, 30% GLYCEROL, 0.067MM PIP3, 0.80MM 14MER EEPSLLKKLLLAPA, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K
|
Resolution 2.40 Å
R-free 0.230
|
|
4QK4
Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to pip2 at 2.8 a resolution
Deposited 2014-06-05
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
218–461(244 aa)
Fragment:UNP residues 218-461
|
Mutation:C247S, C412S
|
PIK (2S)-3-{[(R)-hydroxy{[(1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dihexadecanoate × 1
EDO 1,2-ETHANEDIOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;SF-1, 6% PEG 8000, 0.2M MGOAC, 20% ETHYLENE GLYCOL, 0.067MM PIP2, 0.80MM 14-MER EEPSLLKKLLLAPA, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K
|
Resolution 2.81 Å
R-free 0.241
|
|
7KHT
The acyl chains of phosphoinositide PIP3 alter the structure and function of nuclear receptor Steroidogenic Factor-1 (SF-1)
Deposited 2020-10-22
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
218–461(244 aa)
|
Mutation:C247S, C412S
|
WES (2S)-3-{[(S)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane-1,2-diyl (9E,9'E)di-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;20% PEG 3350 and 0.2 M magnesium formate
|
Resolution 2.50 Å
R-free 0.249
|
|
8DAF
Human SF-1 LBD bound to synthetic agonist 6N-10CA and bacterial phospholipid
Deposited 2022-06-13
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
218–461(244 aa)
|
Not recorded
|
IUW 10-[(3aR,6S,6aR)-3-phenyl-3a-(1-phenylethenyl)-6-(sulfamoylamino)-1,3a,4,5,6,6a-hexahydropentalen-2-yl]decanoic acid (non-preferred name) × 1
PEF DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;277.15 K;Na acetate (pH 4.6), glycerol, PEG 4000
|
Resolution 2.59 Å
R-free 0.281
|
|
8DAF
Human SF-1 LBD bound to synthetic agonist 6N-10CA and bacterial phospholipid
Deposited 2022-06-13
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
218–461(244 aa)
|
Not recorded
|
IUW 10-[(3aR,6S,6aR)-3-phenyl-3a-(1-phenylethenyl)-6-(sulfamoylamino)-1,3a,4,5,6,6a-hexahydropentalen-2-yl]decanoic acid (non-preferred name) × 1
PEF DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;277.15 K;Na acetate (pH 4.6), glycerol, PEG 4000
|
Resolution 2.59 Å
R-free 0.281
|